What people reported about GLP-1 drugs

Choose a question to compare what people reported across 8 GLP-1 brands. These FDA reports show what patients and clinicians filed after a drug was used. They do not show how often an effect happens or prove that the drug caused it.

What matters first

Questions analyzed: 4
GLP-1 brands: 8
FDA reports in the snapshot: 401,158

Choose a question

Why has my GLP-1 stopped working?

Measured on 8 of 8Highest 6.6%

Drug ineffective is one of the most reported terms for every GLP-1 brand. What the counts show, what they cannot show, and why.

Does a GLP-1 injection hurt?

Measured on 5 of 8Highest 11%

Injection-site pain appears more often in FDA reports for some GLP-1 brands than others. See the comparison across eight products.

Does a GLP-1 cause gastroparesis?

Measured on 2 of 8Highest 5.2%

A slow stomach shows up in FDA reports for the semaglutide products, not the others. What that pattern is, and what the lawsuits explain.

How serious are the reports on GLP-1 drugs?

All 8 measuredHighest 57%

FDA marks each report serious or not. The share varies more than fivefold across GLP-1 brands, and the reason is who files them.

Brands included in the report data

These 8 brands had enough reports for the questions above. We compare brand names instead of adding ingredient totals, which would count the same reports twice.

Each product in this section, its drug substance, how it is supplied, and how many FDA reports name it.
Product	Drug substance	Reports naming it
Zepboundsingle-dose pen, single-dose vial, and a multi-dose vial holding four 0.6 mL doses	tirzepatide	70,141 reports
Mounjarosingle-dose pen, single-dose vial, and a multi-dose vial holding four 0.6 mL doses	tirzepatide	93,975 reports
Trulicitysingle-dose pen at 0.75, 1.5, 3 or 4.5 mg — one strength per pen	dulaglutide	88,332 reports
Ozempica 3 mL pen set to one of several doses, holding four doses	semaglutide	66,161 reports
Rybelsusa 3 mg, 7 mg or 14 mg tablet	semaglutide	7,379 reports
Wegovysingle-dose pen or syringe, one strength each; a four-dose pen at 2.4 mg	semaglutide	21,044 reports
Saxendaa 3 mL pen set to 0.6, 1.2, 1.8, 2.4 or 3 mg	liraglutide	10,040 reports
Victozaa pen set to 0.6, 1.2 or 1.8 mg	liraglutide	44,086 reports

401,158 reports in total · read from FDA 2026-08-17 · FDA data last updated 2026-07-30

Why these are not side-effect pages

A side-effect page reads the FDA-approved label. It tells you what a trial measured, in a few thousand people, over a fixed number of weeks, with a known bottom half to the fraction. That is the better document for how often something happens, and it lives at the symptom questions and on each compound guide.

A page here reads the other document. Once a drug is on the market, anyone can file a report, and what gets filed is a different picture from what a trial recorded. It has no denominator and it cannot show cause. What it can show is which products collect which complaints, and where the labels are silent.

So a question earns a page here only when this snapshot answers it better than a label does. Most questions do not, and most of them are answered elsewhere on this site instead of here.

The two limits that shape every page here

There is no denominator. Nobody knows how many people took each drug and did not file anything, so nothing in this section is a rate and nothing here is a risk. Every percentage is a share of that product’s own reports, and the words saying so travel with it.

The snapshot keeps each product’s 25 most-reported terms rather than all of them. A term missing from that list was either never reported or reported and ranked 26th, and there is no way to tell which. Those rows are published as ceilings and never as zeros, which means the gaps these pages show are the smallest gaps the data allows.

The method is set out in full on the dosing-error study, which is the same snapshot asked the question this section grew out of. How every source on this site is graded is on the sourcing methodology.

Questions this section does not answer

What a dose costs, and whether a plan covers it, is on the cost pages. What a label says about a missed dose or a schedule is on the dose pages. How long a pen keeps outside a fridge is on the storage pages. None of those is a report-stream question, and putting a thin version of them here would only compete with the pages that answer them properly.

Neither does this section answer anything about one person. A share of reports is a fact about a pile of paperwork. Whether something is happening to you, and what to do about it, belongs with a clinician who can see the rest of the picture.